Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT06799286Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bms-986012 + nivolumab in Small Cell Lung Cancer (SCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 19 months, Serious Adverse Events at 19 months and 13 more. Started May 2025; status: completed.
02
Drugs
bms-986012 + nivolumab
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT06799286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799286.